249 related articles for article (PubMed ID: 31166599)
21. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Santos RD; Wiegman A; Caprio S; Cariou B; Averna M; Poulouin Y; Scemama M; Manvelian G; Garon G; Daniels S
JAMA Pediatr; 2024 Mar; 178(3):283-293. PubMed ID: 38315470
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
[TBL] [Abstract][Full Text] [Related]
23. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M
Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
[TBL] [Abstract][Full Text] [Related]
26. A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab.
Chao TH; Hsiao PJ; Liu ME; Wu CJ; Chiang FT; Chen ZC; Chen CP; Yeh HI; Lee TH; Chiang CE
J Chin Med Assoc; 2019 Apr; 82(4):265-271. PubMed ID: 30946207
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and safety of alirocumab versus ezetimibe in high cardiovascular risk Chinese patients with hyperlipidemia: ODYSSEY EAST Study-Chinese sub-population analysis].
Han YL; Ma YY; Su GH; Li Y; Li Y; Liu DF; Song R; Li JY
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):593-599. PubMed ID: 32842270
[No Abstract] [Full Text] [Related]
28. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
Henry RR; Müller-Wieland D; Taub PR; Bujas-Bobanovic M; Louie MJ; Letierce A; Ginsberg HN
Diabetes Obes Metab; 2018 Jul; 20(7):1632-1641. PubMed ID: 29493859
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM; Thompson PD; Cannon CP; Guyton JR; Bergeron J; Zieve FJ; Bruckert E; Jacobson TA; Kopecky SL; Baccara-Dinet MT; Du Y; Pordy R; Gipe DA;
J Clin Lipidol; 2015; 9(6):758-769. PubMed ID: 26687696
[TBL] [Abstract][Full Text] [Related]
31. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial.
Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
Rosenson RS; Daviglus ML; Handelsman Y; Pozzilli P; Bays H; Monsalvo ML; Elliott-Davey M; Somaratne R; Reaven P
Diabetologia; 2019 Jun; 62(6):948-958. PubMed ID: 30953107
[TBL] [Abstract][Full Text] [Related]
33. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.
Bays HE; Leiter LA; Colhoun HM; Thompson D; Bessac L; Pordy R; Toth PP
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862926
[TBL] [Abstract][Full Text] [Related]
34. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
Ginsberg HN; Tuomilehto J; Hovingh GK; Cariou B; Santos RD; Brown AS; Sanganalmath SK; Koren A; Thompson D; Raal FJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):69-76. PubMed ID: 30734207
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
[TBL] [Abstract][Full Text] [Related]
36. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Eckel RH; Cannon CP; Lee LV; Bessac L; Pordy R; Letierce A; Ray KK
J Am Heart Assoc; 2018 Sep; 7(18):e009221. PubMed ID: 30371190
[TBL] [Abstract][Full Text] [Related]
37. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
38. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
Ray KK; Ginsberg HN; Davidson MH; Pordy R; Bessac L; Minini P; Eckel RH; Cannon CP
Circulation; 2016 Dec; 134(24):1931-1943. PubMed ID: 27777279
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.
Cariou B; Leiter LA; Müller-Wieland D; Bigot G; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Letierce A; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
Diabetes Metab; 2017 Oct; 43(5):453-459. PubMed ID: 28347654
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.
Leiter LA; Müller-Wieland D; Baccara-Dinet MT; Letierce A; Samuel R; Cariou B
Diabet Med; 2018 Jan; 35(1):121-130. PubMed ID: 28799203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
